Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines

INTRODUCTION: Multiple myeloma (MM) is a heterogeneous disease where cancer-driver mutations and aberrant signaling may lead to disease progression and drug resistance. Drug responses vary greatly, and there is an unmet need for biomarkers that can guide precision cancer medicine in this disease. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Giliberto, Mariaserena, Santana, Leonardo Miranda, Holien, Toril, Misund, Kristine, Nakken, Sigve, Vodak, Daniel, Hovig, Eivind, Meza-Zepeda, Leonardo A., Coward, Eivind, Waage, Anders, Taskén, Kjetil, Skånland, Sigrid S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745900/
https://www.ncbi.nlm.nih.gov/pubmed/36523963
http://dx.doi.org/10.3389/fonc.2022.1040730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745900/
https://www.ncbi.nlm.nih.gov/pubmed/36523963
http://dx.doi.org/10.3389/fonc.2022.1040730

Ejemplares similares